Department of Immunology, Tufts University School of Medicine, Boston, MA, USA.
Remedium Bio, Inc., Needham, MA, USA.
Cartilage. 2023 Dec;14(4):492-505. doi: 10.1177/19476035231158774. Epub 2023 Mar 6.
To determine the characterization of chondrogenic properties of adeno-associated virus type 2 (AAV2)-delivered hFGF18, via analysis of effects on primary human chondrocyte proliferation, gene expression, and cartilage thickness changes in the tibia and meniscus.
Chondrogenic properties of AAV2-FGF18 were compared with recombinant human FGF18 (rhFGF18) relative to phosphate-buffered saline (PBS) and AAV2-GFP negative controls. Transcriptome analysis was performed using RNA-seq on primary human chondrocytes treated with rhFGF18 and AAV2-FGF18, relative to PBS. Durability of gene expression was assessed using AAV2-nLuc and imaging. Chondrogenesis was evaluated by measuring weight-normalized thickness in the tibial plateau and the white zone of the anterior horn of the medial meniscus in Sprague-Dawley rats.
AAV2-FGF18 elicits chondrogenesis by promoting proliferation and upregulation of hyaline cartilage-associated genes, including COL2A1 and HAS2, while downregulating fibrocartilage-associated COL1A1. This activity translates to statistically significant, dose-dependent increases in cartilage thickness within the area of the tibial plateau, following a single intra-articular injection of the AAV2-FGF18 or a regimen of 6 twice-weekly injections of rhFGF18 protein relative to AAV2-GFP. In addition, we observed AAV2-FGF18-induced and rhFGF18-induced increases in cartilage thickness of the anterior horn of the medial meniscus. Finally, the single-injection AAV2-delivered hFGF18 offers a potential safety advantage over the multi-injection protein treatment as evidenced by reduced joint swelling over the study period.
AAV2-delivered hFGF18 represents a promising strategy for the restoration of hyaline cartilage by promoting extracellular matrix production, chondrocyte proliferation, and increasing articular and meniscal cartilage thickness after a single intra-articular injection.
通过分析腺相关病毒 2 型(AAV2)递送的 hFGF18 对原代人软骨细胞增殖、基因表达的影响,以及对胫骨和半月板软骨厚度变化的影响,确定其软骨生成特性。
将 AAV2-FGF18 的软骨生成特性与重组人 FGF18(rhFGF18)进行比较,以磷酸盐缓冲盐水(PBS)和 AAV2-GFP 阴性对照为参照。对用 rhFGF18 和 AAV2-FGF18 处理的原代人软骨细胞进行 RNA-seq 转录组分析,以 PBS 为参照。使用 AAV2-nLuc 和成像来评估基因表达的持久性。通过测量 Sprague-Dawley 大鼠胫骨平台和内侧半月板前角白色区的体重归一化厚度来评估软骨生成。
AAV2-FGF18 通过促进增殖和上调透明软骨相关基因,包括 COL2A1 和 HAS2,同时下调纤维软骨相关基因 COL1A1,从而引发软骨生成。这种活性转化为统计学上显著的、剂量依赖性的增加,在单次关节内注射 AAV2-FGF18 或 6 次每周 2 次 rhFGF18 蛋白治疗后,胫骨平台区域内的软骨厚度增加。此外,我们观察到 AAV2-FGF18 诱导和 rhFGF18 诱导的内侧半月板前角软骨厚度增加。最后,单次注射 AAV2 递送的 hFGF18 相对于多剂量蛋白治疗具有潜在的安全性优势,这表现在研究期间关节肿胀减少。
AAV2 递送的 hFGF18 通过促进细胞外基质产生、软骨细胞增殖和增加关节和半月板软骨厚度,为单次关节内注射后透明软骨的修复提供了一种有前途的策略。